RUBICON · Healthcare · Drug Manufacturers - General
Composite scorecard: 45/100 — Quality 77 · Valuation 0
| Share price | ₹1,511.80 |
| Market cap | ₹23,582 Cr |
| P/E ratio | 91.8 |
| P/B ratio | 18.3 |
| ROCE | 24.3% |
| Book value | ₹78.22 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,754 Cr | ₹247 Cr | 23.0% |
| 2025 | ₹1,284 Cr | ₹134 Cr | 20.0% |
| 2024 | ₹854 Cr | ₹91 Cr | 18.0% |
| 2023 | ₹394 Cr | ₹-17 Cr | 5.0% |
| 2022 | ₹314 Cr | ₹-67 Cr | -12.0% |
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabol